Literature DB >> 11401092

Avascular necrosis in the femoral head secondary to bone marrow infarction in a patient with graft-versus-host disease after unrelated bone marrow transplantation.

A Mori1, S Hashino, S Kobayashi, J Tanaka, Y Yamamoto, M Asaka, M Imamura.   

Abstract

We previously reported a case of bone marrow infarction attributable to acute graft-versus-host disease (GVHD) in a patient with acute lymphoblastic leukemia after unrelated bone marrow transplantation (BMT). Although the bone marrow infarction-induced arthralgia in this patient improved, severe arthralgia appeared again with exacerbation of chronic GVHD, and the arthralgia was strongly correlated with the clinical course of chronic GVHD, i.e., the course of symptoms such as dermal and hepatic GVHD and ocular dryness. Finally, the patient developed avascular necrosis (AVN) in the right femoral head. Serum interleukin (IL)-6 and IL-10 levels were high at the onset of arthralgia but low during remission, and levels of interferon-gamma were undetectable throughout the period of arthralgia. Based on the clinical course and these data, chronic GVHD was thought to have been the major cause of the AVN. Since IL-10 antagonizes various other cytokines that induce GVHD, the increase in IL-10 might have inhibited the development of GVHD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401092     DOI: 10.1007/s002770000253

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Innate regeneration in the aging heart: healing from within.

Authors:  Piero Anversa; Annarosa Leri
Journal:  Mayo Clin Proc       Date:  2013-08       Impact factor: 7.616

2.  Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.

Authors:  Pramod K Mistry; Patrick Deegan; Ashok Vellodi; J Alexander Cole; Michael Yeh; Neal J Weinreb
Journal:  Br J Haematol       Date:  2009-09-03       Impact factor: 6.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.